Clinical trial · Interventional
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
NCT00237120CI-TRIAL-00002808completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelogenous Leukemia in Chronic Phase | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- 3 years overall survival
- measure
- Duration of remaining in chronic phase
Secondary outcomes (2)
- measure
- Cytogenetic response and hematologyc response in every 3 or 6 months with 3 years treatment of Imatinib,
- measure
- Adverse event
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase * Previously untreated with Interferon-alpha * Performance status is normal or capable of only limited self-care Exclusion Criteria: * Patients who are pregnant or possibly pregnant * Significant hepatic diseases * Chronic Myelogenous Leukemia in advanced phase Other protocol-defined inclusion/exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.